araag2/HINT huggingface dataset:
Clinical trial NCT00349115 (phase 2, status: unknown status)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: thalidomide
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:Newly diagnosed multiple myeloma in aged between 18 and 75 years old
        with following mesurable leisons: (serum M-protein ≥ 1 g/dL or urine M-protein ≥ 400
        mg/day) -

        Exclusion Criteria:

        - 1. Smoldering or indolent myeloma 2. ECOG performance status > 3 point 3. Known
        hypersensitivity to cyclphosphamide, thalidomide or dexamethasone 4. Peripheral neuropathy
        or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3 5. Uncontrolled or
        severe cardiovascular disease, including MI within 6 months of enrolment, New York Heart
        Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically
        significant pericardial disease, or cardiac amyloidosis, cardiac ejection fraction <0.5 :
        Severe conduction disorder : Hypotension (sitting systolic BP ≤ 100 mmHg and/or sitting
        diastolic BP ≤ 60 mmHg 6. Impaired hepatic function (AST or ALT ≥ x 3 upper normal,
        T-bilirubin ≥ x 2 upper normal) 7. Creatinine cliearance < 20 ml/min 8. Corrected serum
        calcium ≥ 14 mg/dL 9. Sepsis or current active infection 10. Pregnancy or breast feeding
        11. Uncontrolled Diabetes Mellitus 12. Previous history of Recurrent DVT or pulmonary
        embolism 13. Active ulcers detected by gastroscopy 14. Serious medical or psychiatric
        illness likely to interfere with participation in this clinical study.

        15. Receipt of extensive radiation therapy within 4 weeks
Clinical trial NCT00376194 (phase 2, status: withdrawn)
Conditions: autism, asperger's disorder, child development disorders, pervasive
ICD codes: Z13.41, F84.5
Drugs: dmsa
SMILES: OC(=O)[C@@H](S)[C@@H](S)C(O)=O
Eligibility criteria:

        -  INCLUSION CRITERIA:

        Subjects may be included in the study only if they meet all of the following criteria:

          -  Male or female subjects, four to ten years of age.

          -  Meets research criteria for ASD (specifically, autism, Asperger Disorder, or Pervasive
             Developmental Disorder - Not Otherwise Specified).

          -  Detectable (greater than 0.1 microgram per deciliter) levels of blood lead and/or
             blood mercury.

          -  Each legal guardian must have a level of understanding sufficient to agree to all
             required tests and examinations. Each legal guardian must understand the nature of the
             study and must provide written consent to study protocol.

        EXCLUSION CRITERIA:

          -  History of allergic reaction to sulfur or thiol-containing substances

          -  History of previous chelation therapy for autism

          -  History of uncontrolled epilepsy

          -  Weight less than 15 kg at screening

          -  Presence of a chronic medical condition that might interfere with study participation
             in which study participation would be contraindicated or in which there may be
             clinically significant abnormal baseline laboratory results.

          -  Level of lead above 10 microgram per d, or level of mercury over 44 microgram per
             deciliter (toxic levels that require intervention with chelation and preclude placebo
             assignment) or other evidence of heavy metal toxicity.

          -  Recent (less than two months prior to study entry) initiation of behavior therapy
Clinical trial NCT00309140 (phase 2, status: completed)
Conditions: neoplasms, cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: enzastaurin
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  You must have previously participated in and finished Study H6Q-LC-JCAV (JCAV), Study
             H6Q-LC-JCAY (JCAY), or other enzastaurin clinical pharmacology and biopharmaceutics
             studies. If you have had any other cancer treatment (chemotherapy, radiation,
             anti-cancer hormone therapy), you must have completed it at least 4 weeks ago before
             you can enroll in this study.

          -  You must have a cancer for which no other therapy exists that can prolong your life.
             This may include participants with treated, stable brain cancer.

          -  You must have lesions (areas of cancer in your body) that your doctor can either
             measure or detect.

          -  You either must not be able to become pregnant, (because you've had surgery ["tubes
             tied" or hysterectomy], you've gone through menopause, or you've had previous
             radiation for cancer that made you sterile) or your potential to become pregnant must
             be reduced by the use of an approved birth control method (including intrauterine or
             barrier devices) during and for 3 to 6 months following the study.

          -  You can be either male or female, and must be at least 18 years old.

        Exclusion Criteria:

          -  You must not have received treatment within the last 30 days with a drug other than
             enzastaurin that is still experimental (this means it has not received approval to be
             prescribed, except in a clinical trial).

          -  You must not be pregnant or breastfeeding.

          -  You must not have central nervous system (CNS) tumors (tumors in your brain and spinal
             cord). (However, participants who have stable CNS tumors and are taking steroid
             medication may be included.)

          -  You must not have another serious disorder, including active infections that will
             interfere with your participation in the study.

          -  You must not have a second cancer in addition to your primary cancer. Participants
             with adequately treated skin cancer or who have had another cancer in the past, but
             have been cancer free for more than 2 years, are eligible.
Clinical trial NCT00603408 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    study was discontinued due to lack of accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must be >= 18 years of age

          -  Patients must be newly diagnosed with primary invasive ductal breast adenocarcinoma.

          -  Tumor classified as clinically stage T2, T3 or T4 with any N (NX, N1, N2, or N3).

          -  Tumor does not express the following biomarkers: estrogen receptor, progesterone
             receptor, Her2/neu

          -  Adequate organ function defined as:

               -  Serum Creatinine <= 1.5 x upper limit of institutional normal.

               -  ALT, AST, ALK Phos <= 1.5 x upper limit of institutional normal.

               -  Bilirubin <= 1.5 x upper limit of institutional normal.

               -  Normal left ventricular function (LVEF > 50%) by MUGA or ECHO.

        Exclusion Criteria:

          -  No evidence of distant metastasis present by CT, Bone scan, or physical exam. If the
             bone scan or CT scans demonstrate indeterminate lesions, the nature of these lesions
             should be further clarified by additional testing such as PET or MRI.

          -  No prior malignancies with the exception of curatively treated basal or squamous
             carcinoma of the skin or history of previous malignancies, treated with at least
             greater than 5 years disease free survival.

          -  Women of child bearing potential may not be currently pregnant or breastfeeding at
             time of registration and must agree to use adequate contraception.

          -  Karnofsky Performance Status of <= 70.

          -  Patients with known history neural deficiencies (e.g. peripheral neuropathy).

          -  Patients with a known hearing impairment (hearing loss or severe tinnitus).

          -  Male patients
Clinical trial NCT00902668 (phase 2, status: terminated)
Conditions: breast cancer, radiation toxicity
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, K62.7, G62.82, N46.024, N46.124, T66.XXXS, Z57.1, N52.35
Drugs: lovastatin
SMILES: OC(=O)C1=CN=CC=C1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of invasive or in situ epithelial cancer of the breast

               -  Stage 0, I, or II (Tis, T1, or T2) disease

               -  Unifocal disease (single focus that can be encompassed by breast-conserving
                  surgery)

          -  Has undergone prior surgical resection of the primary lesion (lumpectomy) and axillary
             nodal evaluation (if invasive disease is present)

               -  Negative surgical margins (≥ 1 mm)

          -  Planning to undergo radiotherapy with either standard external beam radiotherapy or
             accelerated partial breast irradiation (interstitial or balloon brachytherapy)

          -  No Paget disease of the nipple

          -  No evidence of distant metastases

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  Karnofsky performance status 70-100%

          -  Transaminases < 3 times upper limit of normal (ULN)

          -  Creatine kinase < 5 times ULN

          -  Creatinine clearance ≥ 30 mL/min

          -  Negative pregnancy test

          -  No active liver or muscle disease

          -  No history of collagen vascular disease (e.g., systemic lupus erythematosus,
             scleroderma, or dermatomyositis)

          -  History of prior malignancy allowed provided life expectancy is ≥ 4 years

          -  No major medical or psychiatric illness that, in the investigator's opinion, would
             prevent completion of study treatment or interfere with follow-up

          -  No contraindication to an HMG-coA-reductase inhibitor

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior radiotherapy to the breast, lung, or mediastinum

               -  Prior radiotherapy to the contralateral breast allowed

          -  No chemotherapy for ≥ 2 weeks prior to, during, and for ≥ 2 weeks after completion of
             radiotherapy

          -  No concurrent cytochrome P450 3A4 inhibitors

          -  Concurrent HMG-coA-reductase inhibitor allowed provided patient is able to switch to
             20 mg of lovastatin per day

          -  Concurrent tamoxifen or an aromatase inhibitor allowed
Clinical trial NCT00278070 (phase 2, status: completed)
Conditions: breast cancer, non small cell lung cancer, prostate cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: vinorelbine oral formulation
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Ages 16 - 75 years

          -  Genders: both

          -  Performance status 0-2 according to the World Health Organization (WHO) scale

          -  Life expectancy of at least 16 weeks

          -  Adequate bone marrow, hepatic and renal functions

          -  Absence of brain metastasis

          -  Metastatic/locally advanced refractory prostate, breast or non-small cell lung cancer
             previously treated with no more than two chemotherapeutic regimens

          -  White blood cells >= 3500/mm^3

          -  Absolute neutrophil count >= 1500/mm^3

          -  Platelets >= 100,000/mm^3

          -  Total serum bilirubin less than 1.5 mg/dl

          -  Serum transaminases less than 2.0 x upper normal limit (UNL) unless attributed to
             liver metastases

          -  Serum creatinine within normal range

        Exclusion Criteria:

          -  Major active infection

          -  More than two prior chemotherapy regimens for metastatic disease

          -  Any of the following within the 12 months prior to starting the study treatment:

               -  myocardial infarction,

               -  severe/unstable angina,

               -  coronary/peripheral artery bypass graft,

               -  congestive heart failure,

               -  cerebrovascular accident or transient ischemic attack, or pulmonary embolism,

               -  cardiac dysrhythmias of grade >/= 2,

               -  atrial fibrillation of any grade, or

               -  heart rate corrected interval (QTc) > 450 msec for males or > 470 msec for
                  females.

          -  Hypertension that cannot be controlled with medications (> 150/100 mmHg despite
             optimal medical therapy)

          -  Ongoing anti-coagulation therapy

          -  Pregnancy or breastfeeding

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration; or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into the
             trial.
Clinical trial NCT00257894 (phase 2, status: terminated)
Conditions: nicotine use disorder, nicotine dependence, smoking, tobacco use disorder
ICD codes: F17.208, F17.209, F17.218, F17.219, F17.228, F17.229, F17.298, F17.200, F17.210, F17.208, F17.209, F17.218, F17.219, F17.228, O99.334, O99.335, Y93.G2, O99.330, O99.331, O99.332, O99.333, Z72.0, P04.2
Drugs: baclofen, placebo
SMILES: CCCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    enrollment was completed with insufficient sample size for publishable results
  
Eligibility criteria:

        Inclusion Criteria:

          -  Smoke at least 10 cigarettes per day for at least 6 months and considering quitting
             smoking in the next 6 months-

        Exclusion Criteria:

          -  Planning to attempt smoking cessation within the next 4 months

          -  Weight less than 110 lbs. or above 220 lbs.

          -  Use of tobacco products other than cigarettes in the previous month.

          -  History of: Kidney disease, uncontrolled conditions (e.g., cardiac disease, pulmonary
             disease, diabetes, hypertension) Neurological disease (including stroke, mini-stroke,
             brain injury, Alzheimers Disease, encephalitis, meningitis, seizure
             disorder),Phenylketonuria Schizophrenia, Schizoaffective Disorder, Paranoid Disorder,
             or Schizotypal Disorder.

          -  Current alcohol and/or drug use disorder as indicated by a screening questionnaire,
             past treatment for alcohol or substance use problems unless in remission(clean and
             sober for past year or more) or intention to seek treatment in the next 6 months for
             alcohol or substance use problems.

          -  For women: Pregnancy, nursing, not using a reliable form of birth control.

          -  Allergy to baclofen, Lioresal, or Kemstro.

          -  Taking the following medications: antidepressants(excluding selective serotonin
             reuptake inhibitors), bupropion, phenothiazines, antihistamines, sedative/hypnotics,
             benzodiazepines, alpha blockers, beta blockers.

          -  Lives with someone enrolled in the study.
Clinical trial NCT00623597 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: ritonavir, saquinavir [invirase]
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  infants and children, 4 months to <6 years;

          -  confirmed HIV-1 infection;

          -  patients for whom saquinavir/ritonavir together with >=2 background ARVs is considered
             appropriate.

        Exclusion Criteria:

          -  body weight >4kg/8.8 pounds;

          -  use of any concomitant medications that may interfere with the pharmacokinetics of
             saquinavir or ritonavir;

          -  malabsorption, severe chronic diarrhea or vomiting within 28 days of the study.
Clinical trial NCT00063102 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: abt-751
SMILES: COC1=CC=C(C=C1)S(=O)(=O)NC1=C(NC2=CC=C(O)C=C2)N=CC=C1
Eligibility criteria:

        Inclusion Criteria

          -  Stage IIIB or IV breast cancer.

          -  Recurrent tumor after or while on taxane therapy (taxol or taxotere).

          -  Able to tolerate normal activities of daily living.

          -  Adequate bone marrow, kidney and liver function.

        Exclusion Criteria

          -  Pregnant or breast feeding.

          -  No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the
             start of ABT-751 administration.
Clinical trial NCT02090153 (phase 2, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: s-1, lv
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2
Eligibility criteria:

        Inclusion Criteria:

          -  histologically conﬁrmed metastatic or recurrent gastric cancer

          -  with at least one measurable lesion by RECIST criteria

          -  an age of ≥ 18

          -  adequate oral intake

          -  no previous radiotherapy, immunotherapy, biotherapy, hormonotherapy and chemotherapy
             within 5 years (adjuvant chemotherapy without S-1 was allowed if ﬁnished 6 months
             before enrollment)

          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  adequate bone marrow function, hepatic function and renal functions

        Exclusion Criteria:

          -  a history of hypersensitivity to S-1 or LV, usage of drugs interacting with S-1

          -  serious concomitant conditions (severe heart disease, pulmonary ﬁbrosis, intestinal
             obstruction, enteroplegia, renal failure, liver failure, pre-existing sensory
             neuropathy ≥ grade 2, uncontrolled infections, psychogenic disorders, human
             immunodeﬁciency virus infection, severe diarrhea, nausea, or vomiting, severe ascites
             or pleural effusion, etc.)

          -  extensive bone metastasis, brain metastasis or meningeal metastasis

          -  another synchronous cancer

          -  surgery within 3 weeks before enrollment

          -  participating in other clinical studies

          -  women who were or to be pregnant, nursing infants, and men who were to conceive
             children
Clinical trial NCT00358956 (phase 2, status: completed)
Conditions: thyroid cancer
ICD codes: C73, D34, D44.0, Z85.850
Drugs: zd6474 (vandetanib)
SMILES: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent

          -  Previously confirmed histological diagnosis of locally advanced or metastatic
             hereditary medullary thyroid carcinoma without standard therapeutic options

          -  Aged 18 or over and a life expectancy of more than 12 weeks

        Exclusion Criteria:

          -  The last dose of prior chemo/radiation received less than 4 weeks before the start of
             study therapy

          -  Congenital long QT syndrome or 1st degree relative with unexplained sudden death under
             40 years of age, history of arrhythmia
Clinical trial NCT00074737 (phase 2, status: completed)
Conditions: acute myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cenersen, idarubicin, cytarabine
SMILES: [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria

          -  Subjects with either refractory AML (not achieving a CR after a single course of
             induction), or relapsed AML that have a CR for less than one year.

          -  greater or equal to 18 years old.

          -  Life expectancy of more than 4 weeks following initiation of treatment.

          -  Performance status (Zubrod) less or equal to 3.

          -  Total Bilirubin less or equal to 1.5 x upper normal limit (UNL) unless attributable to
             organ infiltration by leukemia, and ALT(SGPT) less or equal to 2.5 x UNL.

          -  Creatinine less or equal to 1.5 x UNL unless attributable to organ infiltration by
             leukemia.

          -  If plasma creatinine value is borderline, creatinine clearance greater or equal to 60
             ml/min (actual or calculated), serum magnesium should be within the normal value.

          -  Subjects with liver and/or renal dysfunction due to organ infiltration by leukemia are
             eligible.

          -  Left Ventricular Ejection Volume (LVEF) of >50% as determined by multi-gated
             acquisition scan (MUGA) or echocardiogram.

          -  Able to comply with scheduled follow-up and with management of toxicity.

          -  Sexually active patients must use an effective method of contraception during the
             study dosing period. The following are considered acceptable methods of contraception:
             (i) oral contraceptive pill, (ii) condom, (iii) diaphragm plus spermicide, (iv)
             patient or partner surgically sterile, (v) patient or partner more than 2 years
             post-menopausal or (vi) injectable or implantable agent/device.

          -  Informed consent form obtained, signed and dated prior to initiation of treatment

        Exclusion Criteria:

          -  Subjects with M3 AML.

          -  Subjects receiving other anti-leukemia investigational agents (i.e., unapproved
             drugs). However, individual cases will be considered on a case-by-case basis for other
             investigational agents (e.g., antibiotics, antifungals).

          -  Pregnant or lactating subjects. Chemotherapy (including hydroxyurea) within three (3)
             weeks prior to initiation of therapy, unless there is evidence of rapidly progressive
             disease; then subjects may be enrolled with a minimum of two (2) weeks from previous
             treatments.

        Prohibited Medications during the first week of each course:

          -  Acetaminophen

          -  Hi-Dose antioxidants (e.g., Vitamins C, E; Multivitamins)